Merck (MRK) Exchange Rate Effect (2009 - 2026)
Merck (MRK) reported Exchange Rate Effect of -$19.0 million for Q1 2026, down 112.18% year-over-year from $156.0 million in Q1 2025, and down 182.61% quarter-over-quarter from $23.0 million in Q4 2025.
Merck (MRK) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Exchange Rate Effect data on file, last reported at -$19.0 million in Q1 2026.
- Exchange Rate Effect for Q1 2026 came in at -$19.0 million, down 112.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $388.0 million (up 38700.0% YoY), and the FY2025 annual result was $563.0 million, up 292.15% from the prior year.
- Exchange Rate Effect eased to -$19.0 million in Q1 2026 per MRK's latest filing, from $23.0 million in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $374.0 million in Q2 2025 and troughed at -$412.0 million in Q3 2022.
- A 5-year average of -$8.0 million and a median of -$19.0 million in 2026 frame the typical range for Exchange Rate Effect.
- On a YoY basis, Exchange Rate Effect climbed as much as 638.24% in 2022 and fell as far as 795.65% in 2022.
- A 5-year view of Exchange Rate Effect shows it stood at $366.0 million in 2022, then slumped by 49.18% to $186.0 million in 2023, then slumped by 297.31% to -$367.0 million in 2024, then jumped by 106.27% to $23.0 million in 2025, then plunged by 182.61% to -$19.0 million in 2026.
- Business Quant data shows MRK's Exchange Rate Effect at -$19.0 million in Q1 2026, $23.0 million in Q4 2025, and $10.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 2.70 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 67.00 Mn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | -25.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -12.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -19.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -11.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 19.00 Mn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -48.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -77.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.00 Mn |
| Mar 31, 2026 | -19.00 Mn |
| Dec 31, 2025 | 23.00 Mn |
| Dec 31, 2025 | 23.00 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Jun 30, 2025 | 374.00 Mn |
| Jun 30, 2025 | 374.00 Mn |
| Mar 31, 2025 | 156.00 Mn |
| Mar 31, 2025 | 156.00 Mn |
| Dec 31, 2024 | -367.00 Mn |
| Dec 31, 2024 | -367.00 Mn |
| Sep 30, 2024 | 294.00 Mn |
| Sep 30, 2024 | 294.00 Mn |
| Jun 30, 2024 | -82.00 Mn |
| Jun 30, 2024 | -82.00 Mn |
| Mar 31, 2024 | -138.00 Mn |
| Mar 31, 2024 | -138.00 Mn |
| Dec 31, 2023 | 186.00 Mn |
| Dec 31, 2023 | 186.00 Mn |